Metaplastic Breast Carcinoma: A Rare Entity

2019 ◽  
Vol 3 (1) ◽  
pp. 57-59
Author(s):  
Roshani Shrestha ◽  
Prakash Raj Neupane ◽  
Bandana Satyal
Keyword(s):  
Case Report ◽  
Breast Carcinoma ◽  
Triple Negative ◽  
Invasive Breast Carcinoma ◽  
Rare Entity ◽  
Large Tumor ◽  
Large Tumor Size ◽  
Lymphnode Metastasis ◽  
Rare Malignancy ◽  
Metaplastic Breast Carcinoma

Metaplastic Breast Carcinoma is a rare malignancy among invasive breast carcinoma. The patients usually present with large tumor size, axillary lymphnode metastasis and triple negative. The management of Metaplastic Breast carcinoma largely parallels that of Invasive Breast Carcinoma. In this case report, we found a case of metaplastic breast carcinoma with axillary lymphnode metastasis which is very rare.

scholarly journals Triple negative mixed metaplastic breast carcinoma with squamous and spindle cells in an 84-year-old woman: a rare entity with unclear management strategy and poor prognosis

2012 ◽  
Vol 2012 (feb25 1) ◽  
pp. bcr1020115044-bcr1020115044 ◽  
Author(s):  
S. Murukutla ◽  
V. R. Bhatt ◽  
A. Vivekanandarajah ◽  
C. Coomer ◽  
S. Gupta
Keyword(s):  
Breast Carcinoma ◽  
Poor Prognosis ◽  
Management Strategy ◽  
Triple Negative ◽  
Rare Entity ◽  
Spindle Cells ◽  
Metaplastic Breast Carcinoma

scholarly journals Apocrine Carcinoma of Breast: A Case Report with Review of the Literature

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Jyotsna V. Wader ◽  
Akash Jain ◽  
Suresh J. Bhosale ◽  
Pandurang G. Chougale ◽  
Sujata S. Kumbhar
Keyword(s):  
Case Report ◽  
Androgen Receptor ◽  
Breast Carcinoma ◽  
Invasive Breast Carcinoma ◽  
Apocrine Carcinoma ◽  
Review Of The Literature ◽  
Rare Form ◽  
Breast Malignancy ◽  
Apocrine Metaplasia

Apocrine carcinoma is a very rare form of breast malignancy with an incidence of <1% of female invasive breast carcinoma. We report a case of apocrine carcinoma in a 42-year female with marked adenosis showing apocrine metaplasia and discuss the criteria to diagnose apocrine carcinoma with the emerging concept of androgen receptor positivity with its implication on treatment and management of the patient.

Single-institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC).

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 140-140
Author(s):  
Anna Kaminsky
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Tumor Volume ◽  
Triple Negative ◽  
Volume Reduction ◽  
Tumor Volume Reduction ◽  
Metaplastic Breast Carcinoma

140 Background: Metaplastic breast carcinoma (MBC) is a rare subtype that accounts for <1% of all breast carcinomas. MBC is frequently triple-negative and neoadjuvant chemotherapy (NAC) is often used in triple-negative breast cancer (TNBC). The objective of this analysis is to ascertain response rates of MBC to NAC as compared to non-metaplastic TNBC. Methods: We searched the Magee Women’s Cancer Center of UPMC IRB-approved neo-adjuvant treatment database which contains outcome data on 594 patients treated from 2004-2010. 116 patients with triple negative breast cancer (ER /PR negative or ER /PR weakly positive [H score of 10 or less] and HER2 negative or indeterminate [HER2 1+ or 2+ without amplification by FISH]), were identified. Nine of these TNBCs had metaplastic subtype and two groups were analyzed: metaplastic breast carcinoma (MBC) (N= 9) and non-metaplastic breast carcinoma (NMBC) (N = 107). Tumor volume reduction (TVR), pathologic complete response (pCR), recurrence and mortality were compared in both groups. Results: Average follow-up in MBC group was 43 months and no patients were lost to follow-up. Average tumor size on presentation in MBC group was 4.47 cm while in NMBC group it was 3.33 cm. pCR was noted in 0/9 MBC and 43/107 NMBC cases (p = 0.0253). 6/9 patients had mastectomy, 2/9 had breast conserving surgery (BCS) and 1/9 patients did not have a surgery yet. Average TVR was 28% in MBC cases compared to 74% in NMBCs when cases with pCR were included (p = 0.0001) and 56% when cases with pCR were excluded (p = 0.0202). Follow up on 9 MBC cases revealed 1 recurrence and subsequent death (11%). Follow-up on 64 NMBC patients who failed to achieve pCR revealed 22 recurrences (34%) and 18 of them subsequently died (28%). Follow-up on 43 NMBC cases that achieved pCR revealed 3 recurrences (7%) and 1 death (2%). Conclusions: MBC was characterized by larger size at baseline as compared to NMBC. There were no pCR’s seen in MBC, but some MBC did achieve response that allowed for breast conservation. Although the average tumor volume reduction was significantly less in MBC compared to NMBC, the NMBC that failed to achieve pCR fared much worse than MBC who did not achieve pCR. Therefore, the triple-negative paradox is likely not applicable to MBC.

scholarly journals Expression of Basal-like Biomarkers in Triple-Negative Invasive Breast Carcinoma in Puerto Rico

2012 ◽  
Vol 138 (suppl 2) ◽  
pp. A031-A031 ◽  
Author(s):  
Emmanuel Agosto-Arroyo ◽  
Consuelo Climent ◽  
Cruz M. Nazario ◽  
Mary V. Diaz
Keyword(s):  
Puerto Rico ◽  
Breast Carcinoma ◽  
Triple Negative ◽  
Invasive Breast Carcinoma

scholarly journals Metaplastic breast carcinoma: a rare entity

2009 ◽  
Vol 7 (3) ◽  
pp. 289-293
Author(s):  
Nickos G. Kelessis ◽  
George D. Plataniotis ◽  
Manolis V. Agapitos ◽  
Georgia N. Ioanidou ◽  
Irene T. Georgiou ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Rare Entity ◽  
Metaplastic Breast Carcinoma
Sign in / Sign up

Export Citation Format

Share Document